EyePoint Inc
EyePoint Inc (EYPT) Covered Calls
EyePoint Inc trades in the Biotechnology industry with an IV Rank of 84.92%, high versus the past year. EYPT's highest covered call setup is the $0.50 strike expiring Jan 21, 2028, sorted by theoretical annualized return. It's 66.67% out of the money with 430 days to expiration, a 100.00% return until expiration, and a 84.88% theoretical annualized return. Across the setups shown, annualized returns run from 45.97% to 84.88% at strikes between $0.50 and $0.50, with 430 to 794 days to expiration, as of Nov 17, 2026.
Read more
Running EYPT covered calls helps you generate income from EyePoint Inc shares you already own, turning a long stock position into a yield producing asset. A covered call means holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike. Use our scanner to find the best EYPT covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.
A covered call pairs limited risk with a clear income profile. If EYPT stays below the strike at expiration, you keep the premium and the shares. If it rises above, you deliver the stock at the strike and still pocket the premium. Selling EYPT covered calls works best when implied volatility is elevated, since richer premiums improve the risk reward. Key inputs include strike selection relative to delta, days to expiration, annualized return, and probability of assignment, all of which determine whether a given EYPT covered call is worth writing.
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery.
| 2028-01-21 | 430 | 0.50 | 66.67 | 0.10 | 0.15 | 30.00 | 100.00 | 84.88 | -33.33 | +0.65 | 250 | 0.05 |
| 2029-01-19 | 794 | 0.50 | 66.67 | 0.10 | 0.65 | 30.00 | 100.00 | 45.97 | -33.33 | +1.00 | 174 | 0.55 |
As of Nov 17, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV Rank84.92% High
- Market cap (M$)31
- 52 weeks high-98.59%
- 52 weeks low-3.57%
- Analyst recommendationHold
2.69 - Target price$10.44
3731.90% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-12
- P/E—
- Future P/E—
- EPS (ttm)-3.96
- EPS growth next 5 years22.32%
As of Nov 18, 2026